Content about MPS Group Championships

September 10, 2013

Bausch + Lomb and TheraPearl have teamed up to market the Bausch + Lomb TheraPearl Eye Mask, a new option for consumers suffering from a variety of common ailments, including the most common type of dry eye.

MADISON, N.J. — Bausch + Lomb and TheraPearl have teamed up to market the Bausch + Lomb TheraPearl Eye Mask, a new option for consumers suffering from a variety of common ailments, including the most common type of dry eye. The convenient eye mask can be used for hot and cold therapy by chilling it in the freezer or refrigerator, or heating it in the microwave.

 

August 21, 2013

Bausch + Lomb and TheraPearl have teamed up to market the Bausch + Lomb TheraPearl Eye Mask, a new option for consumers suffering from a variety of common ailments, including the most common type of dry eye.

MADISON, N.J. — Bausch + Lomb and TheraPearl have teamed up to market the Bausch + Lomb TheraPearl Eye Mask, a new option for consumers suffering from a variety of common ailments, including the most common type of dry eye.

August 6, 2013

Valeant Pharmaceuticals announced it has completed its previously announced acquisition of Bausch + Lomb.

LAVAL, Quebec — Valeant Pharmaceuticals on Tuesday announced it has completed its previously announced acquisition of Bausch + Lomb.  

Bausch + Lomb is a global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and Victus.

March 25, 2013

Bausch + Lomb announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public.

ROCHESTER, N.Y. — Bausch + Lomb on Friday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public. The number of shares to be offered and the price range for the proposed offering have not yet been determined, the company stated. 

The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.

February 26, 2013

Bausch + Lomb named Robert Bertolini as president and CFO effective immediately.

ROCHESTER, N.Y. — Bausch + Lomb on Tuesday named Robert Bertolini as president and CFO effective immediately. In this capacity, he will oversee the company's finance, information technology and global quality and operations functions. Bertolini, who assumes CFO responsibilities from Brian Harris, will report to Bausch + Lomb CEO Brent Saunders.  

December 12, 2012

Bausch & Lomb is actively exploring a sale that could command upward of $10 billion, according to a report in The Wall Street Journal published Tuesday.

CHICAGO — Bausch & Lomb is actively exploring a sale that could command upward of $10 billion, according to a report in The Wall Street Journal published Tuesday. 

According to the report, Bausch & Lomb has been entertaining informal inquiries since the announcement that the company may soon issue an initial public offering. If no buyer materializes, the eye care company still plans to pursue an IPO, the report noted.

March 27, 2012

Bausch + Lomb will acquire eye drug maker Ista Pharmaceuticals for $9.10 per share in cash, or approximately $500 million.

MADISON, N.J., and IRVINE, Calif. — Bausch + Lomb will acquire eye drug maker Ista Pharmaceuticals for $9.10 per share in cash, or approximately $500 million.

March 18, 2011

Bausch + Lomb on Friday appointed a clinical professor of ophthalmology to serve as the company's first-ever chief medical officer.

ROCHESTER, N.Y. — Bausch + Lomb on Friday appointed a clinical professor of ophthalmology to serve as the company's first-ever chief medical officer.

As CMO, Calvin Roberts will coordinate B + L's research and development efforts across its vision care, pharmaceuticals and surgical business units.

In addition to his role at Bausch + Lomb, Roberts is a clinical professor of ophthalmology at Weill Medical College of Cornell University. He also is a member of the board of directors at Alimera Sciences, a biopharmaceutical company he co-founded in 2003.